A microtubule-stabilizing agent
Related Products
Labeled Version(s)
22094Docetaxel-d9
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Docetaxel (hydrate)

Item No. 11637

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(αR,βS)-β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-benzenepropanoic acid, 12b-(acetyloxy)-12-(benzoyloxy)-2aR,3,4S,4aS,5,6R,9S,10,11S,12S,12aR,12bS-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, hydrate
CAS Number
700367-34-6
Synonyms
  • DTX
  • NSC 628503
  • RP 56976
  • Taxotel
Molecular Formula
C43H53NO14 • XH2O
Formula Weight
807.9
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 5 mg/mlDMSO: 5 mg/mlDMSO:PBS (pH 7.2) (1:10): 0.1 mg/mlEthanol: 1.5 mg/ml
λmax
229 nm
SMILES
CC(C1=C(C)[C@@H](OC([C@H](O)[C@@H](NC(OC(C)(C)C)=O)C2=CC=CC=C2)=O)C3)(C)[C@]3(O)[C@@H](OC(C4=CC=CC=C4)=O)[C@@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]6O)([H])[C@]6(C)C([C@@H]1O)=O.O
InChi Code
InChI=1S/C43H53NO14.H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;/m0./s1
InChi Key
YWKYKORYUFJSCV-XKIQGVRMSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $59

    Add

    10 mg

    $112

    Add

    50 mg

    $472

    Add

    250 mg

    $1,475

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Docetaxel is a microtubule-stabilizing agent and a semisynthetic derivative of paclitaxel (Item No. 10461).1 It promotes microtubule assembly in a cell-free assay when used at a concentration of 20 µM and is cytotoxic to J774.2 cells (EC50 = 0.05 µM).2 In vivo, docetaxel inhibits tumor growth in several cancer models, including B16 murine melanoma and P388 murine leukemia models.1 Formulations containing docetaxel have been used in the treatment of head and neck, breast, and non-small cell lung cancer, gastric adenocarcinoma, and castration-resistant prostate cancer.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51(18), 4845-4852 (1991).

    2. Swindell, C.S., Heerding, J.M., Krauss, N.E., et al. Characterization of the taxol structure-activity profile for the locus of the A-ring side chain. Bioorg. Med. Chem. Lett. 4(12), 1531-1536 (1994).

    Product Citations

    Zielske, S.P., Chen, W., Ibrahim, K.G., et al. SNHG1 opposes quiescence and promotes docetaxel sensitivity in prostate cancer. BMC Cancer 23(1), 672 (2023).

    Berry, M.R., Fadl-Alla, B.A., Samuelson, J., et al. Investigating PSMA differential expression in canine uroepithelial carcinomas to aid disease-based stratification and guide therapeutic selection. BMC Vet. Res. 18(1), 441 (2022).

    Meyer, F.B., Goebel, S., Spangel, S.B., et al. Metformin alters therapeutic effects in the BALB/c tumor therapy model. BMC Cancer 21(1), 629 (2021).

    Kumar, R., Bhat, T.A., Walsh, E.M., et al. Cytochrome c deficiency confers apoptosome and mitochondrial dysfunction in African-American men with prostate cancer. Cancer Res. 79(7), 1353-1368 (2019).

    Huang, J.J., Corona, A.L., Dunn, B.P., et al. Increased type III TGF-β receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition. Oncogene 38(18), 3402-3414 (2019).